FMC (FMC) investor relations material

Strategic pathways and portfolio transformation

• Two main strategies are being pursued: growing independently with debt reduction and manufacturing restructuring, and exploring strategic options including sale or merger, with significant interest from both strategic and private equity parties.

• New technology and pipeline molecules are the primary focus of external interest, with four new molecules nearing market introduction and two fungicides close to development completion by 2030.

• The portfolio is shifting toward a balance of SDHI fungicides, pesticides, and biologicals, fundamentally transforming the business.

• Shareholder perspectives on a potential sale vary, with newer shareholders more likely to accept a $30/share offer, while long-term holders and management see higher standalone value.

Financial management and refinancing plans

• A $500 million debt maturity in October will be addressed through a likely public bond offering in Q2, with sufficient liquidity available if needed.

• The revolving credit facility is being renegotiated to provide more operational flexibility and align with the company's BB+ rating.

• Debt reduction remains a key pillar of the 2026 operating plan, with ongoing efforts to lower absolute debt levels.

Market dynamics and geopolitical impacts

• The ongoing conflict in Iran currently impacts logistics more than costs, but a prolonged conflict (over six months) could increase raw material and energy costs, affecting operations.

• Both India-U.S. and China-U.S. shipping routes are affected, with the potential for broader industry-wide cost increases if disruptions persist.